Form 4: Treace Medical Concepts Director James Treace Acquires 25,000 Shares
SEC Form 4 Filing
Director James Treace of Treace Medical Concepts, Inc. (TMCI) purchased 25,000 shares of common stock at a weighted average price of $6.0531 on May 31, 2024.
Summary
- On May 31, 2024, James Treace, a director at Treace Medical Concepts, Inc. (TMCI), acquired 25,000 shares of common stock.
- The shares were purchased at a weighted average price of $6.0531, with individual prices ranging from $5.9400 to $6.1800.
- Following the transaction, Mr. Treace directly owns 1,139,441 shares and indirectly owns 556,183 shares through his spouse.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of a stock purchase by a director, which can be seen as a mildly positive signal, but it's not a major event.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This purchase indicates the director's confidence in the company.
Stakeholder Impact
- The stock purchase by a director could have a slightly positive impact on shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 05/31/2024 | Date of transaction: James Treace purchased 25,000 shares of TMCI common stock. |
| 06/03/2024 | Date of report: Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.